intellectual property rights | Institut Fraser

Who was Barbara Mitchell?

Janvier 30, 2017 4:46PM

Canada’s inadequate intellectual property rights protections hurt patients and the economy

Kristina M.L. Acri, née Lybecker

There are numerous deficiencies that weaken intellectual property protections within Canada relative to other industrialized countries.

Étiquettes:

intellectual property rights, intellectual property for pharmaceuticals, intellectual property protection, pharmaceutical innovation, biologics, pharmaceutical manufacture

Janvier 24, 2017 1:00AM

Intellectual Property Rights Protection and the Biopharmaceutical Industry: How Canada Measures Up

Kristina M.L. Acri, née Lybecker

Intellectual Property Rights Protection and the Biopharmaceutical Industry: How Canada Measures Up

Étiquettes:

intellectual property rights, intellectual property for pharmaceuticals, intellectual property protection, pharmaceutical innovation, biologics, pharmaceutical manufacture

Octobre 14, 2016 1:30AM

Intellectual Property Rights and the Promotion of Biologics, Medical Devices, and Trade in Pharmaceuticals

Steven Globerman, Kristina M.L. Acri, née Lybecker, Christopher Sands, Tomas J. Philipson

Intellectual Property Rights and the Promotion of Biologics, Medical Devices, and Trade in Pharmaceuticals

Étiquettes:

intellectual property rights, intellectual property for pharmaceuticals, intellectual property protection, pharmaceutical innovation, biologics, pharmaceutical manufacture

Juin 28, 2016 3:00AM

Worsening U.S.-China trade relations will likely slow economic growth in Canada

Steven Globerman

Chinese companies are increasingly laying claim to patents, even if they were not the first to develop the broader technology.

Étiquettes:

trade with china, donald trump, hillary clinton, intellectual property rights, apple products

Juillet 22, 2013 2:00AM

Stronger intellectual property for pharmaceuticals would benefit Canadians

Canada's lagging intellectual property (IP) protections for pharmaceutical innovators are a key issue to be settled in the Comprehensive Economic and Trade Agreement (CETA) negotiations with the European Union. They may also play a role in upcoming negotiations for the multi-country Trans-Pacific Partnership (TPP). Two new essays on the cost and benefits of stronger protection suggest Canadians would be far better off, in both economic and health terms, with an IP protection regime for pharmaceutical innovators that was more closely aligned with international standards.

Étiquettes:

intellectual property rights, pharmaceutical industry, intellectual property for pharmaceuticals, new medicine, new drugs, property rights, trade, CETA, TPP, trans-pacific partnership

Décembre 31, 1999 6:00PM

Competitive Strategies for the Protection of Intellectual Property

Carsten Fink, Owen Lippert

Étiquettes:

canadian intellectual property protection, intellectual property rights